MedPath

A 24 weeks, randomized, double-blind, placebo-controlled human trial of Allium fistulosum L. root extract on improvement of child height growth

Not Applicable
Recruiting
Conditions
Not Applicable
Registration Number
KCT0005981
Lead Sponsor
Daejeon Korean Medicine Hospital of Daejeon University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

1) Children before adolescence, 3~ 25 percentile based on 2017 Korea standard growth chart percentile
2) Spontaneously agreed to participate in the study by the patients and legal guardians or parents

Exclusion Criteria

1) Participants who have taken Hormone replacement therapy or calcitonin, Phosphonate, growth hormone within 6 month prior to the screening examination
2) Participants with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.)
3) Participants who take medicine or health functional food for improvement of child height growth within 3 month prior to the screening examination
4) Participants with a history of antipsychotic medication use within 3 months prior to the screening examination
5) Participantts who have participated in other clinical trials within 3 months prior to the screening examination
6) Participants who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Height
Secondary Outcome Measures
NameTimeMethod
IGF-1(Insulin-like growth factor-1);IGFBP-3(Insulin-like growth factor binding protein-3);Growth Hormone
© Copyright 2025. All Rights Reserved by MedPath